0001493152-21-010808.txt : 20210507 0001493152-21-010808.hdr.sgml : 20210507 20210507192342 ACCESSION NUMBER: 0001493152-21-010808 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210506 FILED AS OF DATE: 20210507 DATE AS OF CHANGE: 20210507 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: 22NW, LP CENTRAL INDEX KEY: 0001694297 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40388 FILM NUMBER: 21904772 BUSINESS ADDRESS: STREET 1: 1455 NW LEARY WAY, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98107 BUSINESS PHONE: 206-437-9174 MAIL ADDRESS: STREET 1: 1455 NW LEARY WAY, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: English Aron R. CENTRAL INDEX KEY: 0001770436 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40388 FILM NUMBER: 21904773 MAIL ADDRESS: STREET 1: 1455 NW LEARY WAY, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Anebulo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001815974 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851170950 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1415 RANCH ROAD 629 SOUTH, SUITE 201 CITY: LAKEWAY STATE: TX ZIP: 78734 BUSINESS PHONE: 737 203 5270 MAIL ADDRESS: STREET 1: 1415 RANCH ROAD 629 SOUTH, SUITE 201 CITY: LAKEWAY STATE: TX ZIP: 78734 4 1 ownership.xml X0306 4 2021-05-06 0 0001815974 Anebulo Pharmaceuticals, Inc. ANEB 0001770436 English Aron R. C/O ANEBULO PHARMACEUTICALS, INC. 1415 RANCH ROAD 620 SOUTH, SUITE 201 LAKEWAY TX 78734 1 0 1 1 See Explanation of Responses 0001694297 22NW, LP 1455 NW LEARY WAY, SUITE 400 SEATTLE WA 98107 0 0 1 1 See Explanation of Responses Common Stock, par value $0.001 per share 2021-05-06 4 A 0 714286 7.00 A 3343601 I 22NW, LP Common Stock, par value $0.001 per share 4654528 I Pharma Investors, LLC This Form 4 is filed jointly by Aron R. English and 22NW, LP (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Securities owned directly by 22NW, LP. Mr. English, as the President of 22NW, LP, may be deemed to beneficially own the securities owned directly by 22NW, LP. Securities owned directly by Pharma Investors, LLC. Mr. English, as the owner of Pharma Investors, LLC, may be deemed to beneficially own the securities owned directly by Pharma Investors, LLC. Please note that this Form 4 corrects information that was previously reported on the Reporting Persons' Form 3 filed with the U.S. Securities and Exchange Commission on May 6, 2021 (the "Form 3"). Footnote 3 of the Form 3 is hereby corrected to state that Mr. English is the owner of Pharma Investors, LLC, not the owner of 22NW, LP. /s/ Rex Merchant, as Attorney-in-Fact 2021-05-07 22NW, LP; By: /s/ Rex Merchant, as Attorney-in-Fact 2021-05-07